Published 11/06/2009 by HIV and Hepatitis.com
Entecavir (Baraclude) Demonstrates Greater Antiviral Activity than Adefovir (Hepsera) in Hepatitis B Patients with Decompensated Liver Disease
To explore this issue, an international team of investigators conducted a randomized, open-label, Phase 3b study (ETV-048) comparing 1.0 mg/day entecavir versus 10 mg/day adefovir in this population. A total of 100 participants randomly assigned to the...
Share this
What others report on the same story